Sitagliptin — enhancing incretin action

Abstract

DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

Keywords

DPP-4 gliptin incretin inhibitor sitagliptin type 2 diabetes

Get full access to this article

View all access options for this article.

References

Creutzfeldt W. The [pre-] history of the incretin concept . Regul Pep 2005;128:87-91.

McIntyre N. , Holdsworth CD , Turner DS New interpretation of oral glucose tolerance. Lancet 1964;2:20-21.

Elrick H. , Stimmler L. , Hlad CJ , Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.

Unger RH , Eisentraut AM Entero-insular axis. Arch Int Med 1969;123:261-6.

Marks V. , Morgan L. The entero-insular axis in Recent advances in diabetes, Nattrass M, Santiago (eds) Churchill Livingstone, London 1984;1:55-71.

Nauck M. , Stockmann F. , Ebert R. , Creuzfeldt W. Reduced incretin effecting type 2 (non-insulin-dependent) diabetes . Diabetologia 1986;29:46-52.

Nauck MA , Heimesaat MM , Orskov C. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-07.

Estall JL , Drucker DJ Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006;12:1731-50.

Drucker DJ The biology of incretin hormones. Cell Metabolism 2006;3:153-65.

10.

Drucker DJ The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.

11.

Green BD , Flatt PR , Bailey CJ Dipeptidyl peptidase 4 (DPP 4) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 2006;3:159-65.

12.

Bailey CJ Oral antidiabetic drugs. Encyclopedia of Molecular Pharmacology Offermans S , Rosenthal W (eds) Springer (in press).

13.

Sitagliptin , Summary of Product Characteristics http://emc.medicines.org.uk/

14.

Herman G. , Bergman A. , Wagner JA Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia 2006;49:(suppl 1) Abstract 0795.

15.

Hermann G. , Hanefeld M. , Wu M. et al. Effect of MK-0431, a dipeptidyl peptidase 4 (DPP-4) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 2005;54:Abstract 541-P.

16.

Nonaka K. , Kakikawa T. , Sato et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes. Diabetologia 2006;49(suppl1):Abstract 0038.

17.

Raz I. , Hanefeld M. , Xu L. et al. Efficacy and safety of sitagliptin over 18 weeks in patients with type 2 diabetes. Diabetologia 2006;49:(suppl 1).Abstract 0794.

18.

Aschner P. , Kipnes M. , Lunceford J. et al. Effect of the dipeptidyl peptidase-4 sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.

19.

Goldstein BJ , Feinglos MN , Lunceford et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care (in press), published online May 7 2007.

20.

Rosenstock J. , Brazg R. , Andryuk P. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter , Clin Therapeutics 2006;28:1556-68. randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics 2006;28:1556-68.

21.

Nauck MA , Meininger G. , Sheng D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately confonylurea, glipizide, in patients with type 2 diabete de ately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.

22.

Charbonnel B. , Karisik A. , Liu J. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.

23.

Brazg R. , Xu L. , Dalla Man C. et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and b-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93.

24.

Nathan DM , Buse JB , Davidson ME et al. Management of hyperlgycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21 and Diabetes Care 2006;29:1963-72.

25.

Mistry G. , Bergman A. , Wen-Lin L. et al. Effects of sitagliptin on the pharmacokinetics (PK) of rosiglitazone in healthy subjects. Diabetes 2006; Abstract 2001-PO.

26.

Ruddy MK , Bergman AJ , Zheng W. et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Diabetes 2006 .Abstract 558-P.

27.

Vilsboll T. , Knop FK DPP 4 inhibitors current evidence and future directions. Br J Diabetes Vasc Dis 2007;2:69-74.